Vera Therapeutics, Inc. (VERA)

Market Cap	1.70B
Revenue (ttm)	n/a
Net Income (ttm)	-152.15M
Shares Out	63.75M
EPS (ttm)	-2.75
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	530,032
Open	26.55
Previous Close	26.52
Day's Range	26.07 - 26.89
52-Week Range	25.55 - 51.61
Beta	1.16
Analysts	Buy
Price Target	65.50 (+145.96%)
Earnings Date	May 8, 2025

About VERA

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in phase 3 trial for the treatment of immunoglobulin A nephropathy. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections which is completed phase 2 clinical trial; and VT-109, a fusion protein targets B-cell activating fac...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 14, 2021
• Employees: 112
• Stock Exchange: NASDAQ
• Ticker Symbol: VERA
• Website: https://veratx.com

Analyst Forecast

According to 8 analysts, the average rating for VERA stock is "Buy." The 12-month stock price forecast is $65.5, which is an increase of 145.96% from the latest price.

Price Target

$65.5

(145.96% upside)

Analyst Consensus: Buy